SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

NBI-1117570

NBIX·NEUROCRINE BIOSCIENCES INC
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 2a
Time to market
If successful through Phase 2a, Phase 3, and FDA review, potential approval would likely be several years away (late 2020s or early 2030s at the earliest), given the Phase 2a data readout is not expected until 2028.
Why 2/10
No hard, dated binary catalyst is scheduled within the next ~12 months. The Phase 2a trial (NCT07288333) has an estimated primary completion of August 2027 and topline data expected in 2028. NBI-1117570 is one of several early-to-mid-stage pipeline assets at a diversified commercial-stage company with three marketed products generating over $1.1B in quarterly revenue, so this single drug drives a very small portion of NBIX's valuation.
Actionable Insight NEUTRAL

NBI-1117570 is an early-stage (Phase 2a) pipeline asset with no near-term binary catalyst. The next meaningful event is the Phase 2a topline readout, currently estimated for 2028. For NBIX investors, the stock's near-term drivers are commercial execution of INGREZZA, CRENESSITY, and VYKAT XR, plus Phase 3 data from the more advanced sister asset direclidine (NBI-1117568) expected in 2027-2028.

Price Chart

Loading chart...

Executive Summary

NBI-1117570 (NBI-570) is an investigational oral, dual M1/M4 muscarinic receptor agonist being developed by Neurocrine Biosciences (NBIX) for schizophrenia. It is currently in a Phase 2a inpatient study (NCT07288333) that began dosing in April 2026, targeting approximately 120 patients with an estimated primary completion of August 2027 and topline data expected in 2028. The drug was discovered by Nxera Pharma using its NxWave platform and is the second muscarinic compound from that collaboration to reach Phase 2, following direclidine (NBI-1117568) which is already in Phase 3. NBI-1117570 works through the same validated mechanism as BMS's approved Cobenfy (KarXT), the first new class of schizophrenia drugs in decades. However, as an early-stage pipeline asset at a diversified commercial-stage company with three marketed products generating over $1.1B in quarterly revenue, this drug represents a small portion of NBIX's current valuation with no near-term binary catalyst.

How It Works

NBI-1117570 is an oral pill that activates two specific muscarinic receptors in the brain called M1 and M4. These receptors help regulate brain signaling related to cognition and psychosis. Unlike older schizophrenia drugs that block dopamine receptors (causing side effects like movement disorders), this drug works through a different pathway. It belongs to the same class as Bristol Myers Squibb's recently approved schizophrenia drug Cobenfy (KarXT), which was the first new mechanism of action for schizophrenia in decades.

Trial Status

The Phase 2a study (NCT07288333) is a multicenter, randomized, double-blind, placebo-controlled inpatient trial in adults with schizophrenia who warrant inpatient hospitalization. The study started on February 16, 2026, and the first patient was dosed in April 2026, triggering a $22.5M milestone payment to Nxera Pharma. The trial is currently recruiting with an estimated enrollment of 120 patients across 5-6 sites in 3 countries. Estimated primary completion is August 2027, with topline data expected in 2028.

The Two-Sided Case

▲ Bull Case4
NBI-1117570 is a dual M1/M4 muscarinic agonist, a mechanism validated by BMS's approved Cobenfy (KarXT), which generated over $10B in peak sales estimates and represents the first new class of schizophrenia drugs in decades.
The drug was discovered by Nxera Pharma using its NxWave platform and is the second NxWave-designed muscarinic compound in Neurocrine's portfolio to reach Phase 2, suggesting a systematic platform approach.
Neurocrine is a well-capitalized, diversified commercial-stage biotech with Q3 2026 revenue exceeding $1.1B and strong analyst consensus (32 analysts, mean price target $206, 41.9% implied upside), providing ample resources to develop the pipeline.
The Phase 2a study initiation triggered a $22.5M milestone payment to Nxera, indicating Neurocrine's commitment to advancing the program.
▼ Bear Case4
NBI-1117570 is early-stage (Phase 2a) with primary completion not expected until August 2027 and topline data in 2028, meaning no near-term catalyst for years.
The muscarinic agonist space is increasingly competitive: BMS's Cobenfy (KarXT) was approved in September 2024 as the first schizophrenia drug with this mechanism, and Neurocrine's own more advanced asset direclidine (NBI-1117568) is already in Phase 3, potentially making NBI-1117570 a follow-on compound.
Phase 2 schizophrenia trials have a high historical failure rate, and the drug's dual M1/M4 profile carries unknown safety/tolerability risks compared to the M4-selective approach of direclidine.
Neurocrine's stock has significant insider selling (CFO, Chief Corp Affairs Officer sold shares in September 2026 under 10b5-1 plans) and several large institutional holders trimmed or exited positions in Q2 2026.

Upcoming Catalysts

  • Phase 2a topline data readout (estimated 2028)
  • Potential Phase 3 initiation decision following Phase 2a results

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report

Sources · 10

Hover a chip for the title
1 biospace.com2 clinicaltrials.gov3 cnspulse.com4 cnspulse.com5 adisinsight.springer.com6 adisinsight.springer.com7 prnewswire.com8 neurocrine.com9 synapse.patsnap.com10 spzco.com